It’s becoming more and more common for senior, scientific executives to leave big drug companies either for small biotech companies or start-up initiatives. At times, of their own volition, these leaders make this transition despite enjoying a key leadership position with major responsibilities in a big company setting. A year ago, Dr. Joel Barrish, now the Chief Scientific Officer of Achillion, made such a move.
